Table 1.

Patient’s cohort characteristics of the HNPC cohort.

Age, years :
Mean	64.5
Median	65.0
Range	47.1–75.0
PSA, ng/ml:
Mean	14.2
Median	9.4
Range	1.4–113.0
Prostate weight, gr:
Mean	55.6
Median	50.0
Range	10.0–210.0
Clinical stage, No (%):
T1	175 (67.8)
T2 or more	83 (32.2)
Gleason score, No (%):
≤6	123 (47.7)
7	73 (28.3)
≥8	62 (24.0)
pT stage, No (%):
pT2	150 (58.1)
pT3	86 (33.4)
pT4	22 (8.5)
Extraprostatic extension, No (%):	96 (37.2)
Positive margins, No (%):	56 (21.7)
Seminal vesicle invasion, No (%):	56 (21.7)
Positive lymph nodes, No (%):	23 (8.9)
Duration of follow-up, months:
Mean	61.5
Median	48.3
Range	0.6–170.7
Recurrence, No (%):	62 (24.0)

Clinico-pathological characteristics of patients with clinically hormone naïve prostate cancer (n=258).

HNPC: hormone naive prostate cancer.